Not sure if this has been spoken about here. In recent presentations Gary indicated SNT would be speaking with the FDA in Q1 25.
In the Dec 4 announcement….. “Moreover, the trial is not sufficiently advanced to havegenerated enough data for SNT to approach the FDA on the study design for apivotal trial – the next milestone in development of the drug.”
P2 Trial won’t be complete till August 25 now so I guess the meeting with the FDA will be parked to later Q2/3.
Add to My Watchlist
What is My Watchlist?
